Vistagen therapeutics reports fiscal 2021 second quarter financial results and provides highlights on its cns pipeline and business progress

South san francisco, calif., nov. 12, 2020 /prnewswire/ -- vistagen therapeutics (nasdaq: vtgn), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (cns) disorders, today reported its financial results for the fiscal...
VTGN Ratings Summary
VTGN Quant Ranking